MARKET

BCRX

BCRX

Biocryst Pharmaceuticals Inc
NASDAQ
4.430
-0.070
-1.56%
After Hours: 4.430 0 0.00% 19:23 04/19 EDT
OPEN
4.500
PREV CLOSE
4.500
HIGH
4.590
LOW
4.270
VOLUME
4.69M
TURNOVER
0
52 WEEK HIGH
9.07
52 WEEK LOW
4.270
MARKET CAP
913.24M
P/E (TTM)
-3.7584
1D
5D
1M
3M
1Y
5Y
FYBR, BCRX and SABR are among after hour movers
Seeking Alpha · 3d ago
BioCryst: Brazilian Health Regulatory Agency Approves ORLADEYO - Quick Facts
NASDAQ · 5d ago
BIOCRYST ANNOUNCES APPROVAL OF ORLADEYO® (BEROTRALSTAT) BY THE BRAZILIAN HEALTH REGULATORY AGENCY
Reuters · 5d ago
BUZZ-US health insurers rise on UnitedHealth's upbeat Q1 profit
Shares of U.S. Health insurers rise between 2% and 5% in premarket trading after UnitedHealth Group UNH.N reports upbeat Q1 results. UnitedHealth maintains 2024 forecast despite disruptions caused by February cyberattack. Humana, CVS Health and Cigna also rise on UnitedHealth's results.
Reuters · 5d ago
Weekly Report: what happened at BCRX last week (0408-0412)?
Weekly Report · 04/15 09:03
RBC Capital Keeps Their Buy Rating on BioCryst (BCRX)
TipRanks · 04/14 06:36
Optimizing Investment Strategies: A Deep Dive into BioCryst’s Stock Performance
TipRanks · 04/10 10:55
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 04/09 03:00
More
About BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.

Webull offers BioCryst Pharmaceuticals Inc stock information, including NASDAQ: BCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCRX stock methods without spending real money on the virtual paper trading platform.